Collaboration with Europe’s leading cancer hospital - largest clinical trial on 3D printed medicine

25 July 2024

Researchers from UCL School of Pharmacy have published their recent collaboration with FABRX, a UCL School of Pharmacy spinout, and Gustave Roussy, Europe’s leading cancer research hospital, for the development of multi-active medicines produced via 3D printing

Anna Kirstine Jørgensen, PhD student in the Centre for Doctoral Training (CDT) for Transformative Pharmaceutical Technologies, and Professor Abdul Basit from UCL School of Pharmacy have published their recent collaboration with FABRX and Gustave Roussy Cancer Campus on the development of personalised breast cancer medicines with multiple actives through a pharmaceutical 3D printer. The medicines are included in the largest clinical trial on medicines produced via 3D printing to date where they will treat 200 breast cancer patients to help improve adherence to tamoxifen.

The personalised medicines containing tamoxifen and antidepressants are included in a clinical trial in 200 breast cancer patients, the largest clinical trial on 3D printed medicines to date.

To read the publication, please visit: https://doi.org/10.1016/j.ijpharm.2024.124306

Collaborators’ websites: FABRX & Gustave Roussy Cancer Campus

For any queries or more information, please contact Prof Abdul Basit (a.basit@ucl.ac.uk)